John Marchica

John Marchica

Auto-generated profile, based on publicly available information

John Marchica

Johns Hopkins All Children’s Hospital, St. Petersburg, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2020 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
BLBongyong Lee
Bongyong Lee
ASAnupama Sahoo
Anupama Sahoo
JSJunko Sawada
Junko Sawada
JMJohn Marchica
John Marchica
SSSanjay Sahoo
Sanjay Sahoo
RPRanjan Perera
Ranjan Perera

8 June 2021 in Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
BLBongyong Lee
Bongyong Lee
JLJian-Liang Li
Jian-Liang Li
JMJohn Marchica
John Marchica
MMMark Mercola
Mark Mercola
VPVipul Patel
Vipul Patel
RPRanjan Perera
Ranjan Perera

1 February 2023
Verified
Book
Closed access
JKJames R. Knickman
James R. Knickman
BEBrian Elbel
Brian Elbel
SJSteven Jonas
Steven Jonas
AKAnthony R. Kovner
Anthony R. Kovner
ALAmy Yarbrough Landry
Amy Yarbrough Landry
IMIan Morrison
Ian Morrison
This comprehensive textbook contains information on a wide array of topics, including the organization of care, population health, the fundamental challenges of health disparities, health care financing and economics, and health information technology’s role in improving care and protecting privacy. New chapters on public health preparedness and its role in mitigating effects on health and the health system and the medical and social challenges of caring for older adults provide insight into important, ongoing challenges and what those challenges reflect about our system of care. With an increased emphasis on health disparities, population health, and health equity, this textbook includes a timely focus on how social and behavioral determinants influence health outcomes. Students will gain a deeper understanding of public health systems and their societal role and of the economic perspectives that drive health care managers and the system. Thorough coverage of the rapid changes that are reshaping our system, in addition to an evaluation of our nation’s achievement of health care value, will equip students with the critical knowledge they need to enter this dynamic and complex field. The book also includes cutting-edge, evidence-based information on preventive medicine, innovative approaches to control health care costs, initiatives to achieve high-quality and value-based care, and much more from prominent scholars, practitioners, and educators within health care management, public health, population health, health policy, medical care, and nursing.

4 April 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
BLBongyong Lee
Bongyong Lee
IMIqbal Mahmud
Iqbal Mahmud
JMJohn Marchica
John Marchica
PDPaweł Dereziński
Paweł Dereziński
FQFeng Qi
Feng Qi
RPRanjan Perera
Ranjan Perera
Sensitive and specific diagnostic and prognostic biomarkers for prostate cancer (PCa) are urgently needed. Urine samples are a non-invasive means to obtain abundant and readily accessible “liquid biopsies”. Herein we used urine liquid biopsies to identify and characterize a novel group of urine-enriched RNAs and metabolites in PCa patients and normal individuals with or without benign prostatic disease. Differentially expressed RNAs were identified in urine samples by deep sequencing and metabolites in urine were measured by mass spectrometry. The mRNA and metabolite profiles were distinct in patients with benign and malignant disease. Integrated analysis of urinary gene expression and metabolite signatures unveiled an aberrant glutamate metabolism and tricarboxylic acid (TCA) cycle node in prostate cancer-derived cells. Functional validation supports a role for glutamate metabolism and glutamate oxaloacetate transaminase 1 (GOT1)-dependent redox balance in prostate cancer, which can be exploited for novel biomarkers and therapies.

13 February 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
BLBongyong Lee
Bongyong Lee
ASAnupama Sahoo
Anupama Sahoo
JSJunko Sawada
Junko Sawada
JMJohn Marchica
John Marchica
SSSanjay Sahoo
Sanjay Sahoo
RPRanjan Perera
Ranjan Perera
The microRNA MIR211 is an important regulator of melanoma tumor cell behavior. Previous studies suggested that in certain tumors, MIR211 acted as a tumor suppressor while in others it behaved as an oncogenic regulator. When MIR211 is expressed in BRAFV600E-mutant A375 melanoma cells in mouse xenografts, it promotes aggressive tumor growth accompanied by increased cellular proliferation and angiogenesis. We demonstrate that MIR211 is transferred to adjacent cells in the tumor micro-environment via exosomes. Cross-species genome-wide transcriptomic analysis showed that human tumor-derived MIR211 interacts with the mouse transcriptome in the tumor microenvironment, and activates ERK5 signaling in human tumor cells via the modulation of a feedback loop. Human miR211 directly inhibits human DUSP6 protein phosphatase at the post-transcriptional level. We provide support for the hypothesis that DUSP6 inhibition conferred resistance of the human tumor cells to the BRAF inhibitor vemurafenib and to the MEK inhibitor cobimetinib, with associated increases in ERK5 phosphorylation. These findings are consistent with a model in which MIR211 regulates melanoma tumor proliferation and BRAF inhibitor resistance by inducing ERK5 signaling within the complex tumor microenvironment. We propose that the MIR211-ERK5 axis represents an important and sensitive regulatory arm in melanoma with potential theranostic applications.

1 February 2023
Verified
Book Chapter
Open access
PDF file
JKJames R. Knickman
James R. Knickman
JMJohn Marchica
John Marchica
DRDavid C. Radley
David C. Radley
Health care costs are a burden for families, government, and employers. The United States needs to balance affordability of health care with investments in life-enhancing treatments. Health care industry is one of the largest parts of the American economy, accounting for over 20% of our gross domestic product. Medical care restores health more than it ensures a population is healthy over its life span. The United States has developed an insurance system to overcome the obstacle of high costs and pay for services collectively. Public insurance programs, such as Medicare, Medicaid, and Children’s Health Insurance Program (CHIP), and private insurance companies, such as UnitedHealthcare, Aetna, and Kaiser Permanente, work differently. A key question is how much should be spent on population health and how much on recovery-oriented medical care. Strategies and planning to keep people healthy could include public health initiatives, prevention initiatives, and social policies that make healthy choices possible and likely.